Vilain K, Li H, Kwong WJ, et al. Cardiovascular- and bleeding-related hospitalization rates with edoxaban versus warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial. Circ Cardiovasc Qual Outcomes. 2020;13(11):843-852.
https://doi. org/10.1161/CIRCOUTCOMES.120.006511
Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5(1):1-18. https://pubmed.ncbi.nlm.nih.gov/26935434/
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. https://pubmed.ncbi.nlm.nih.gov/24251359/
Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. https://pubmed.ncbi.nlm.nih.gov/23991658/
ncbi.nlm.nih.gov
Srinivasan S, Ajmal M, Pecci C, Lassar T. Edoxaban in cardiovascular disease management: Review. Br J Clin Pharmacol. 2022 Feb;88(2):535-540. doi: 10.1111/bcp.15026. Epub 2021 Dec 9. PMID34365675.
